Lymphoma, B-Cell Clinical Trial
Official title:
Rituximab + Standard CHOP (R・S-CHOP) vs Rituximab+ Bi-weekly CHOP (R・Bi-CHOP) RCT(Phase II/III) for Stage III/IV Low-grade B-cell Lymphoma (LowBNHL-RS/BiCHOP-P2/3) (JCOG0203)
To establish standard therapy for patients with advanced-stage low grade B-cell lymphoma
Status | Completed |
Enrollment | 300 |
Est. completion date | February 2010 |
Est. primary completion date | February 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years to 69 Years |
Eligibility |
Inclusion Criteria: 1. Histological confirmed, low-grade B-cell lymphoma except mantle cell lymphoma and histologic transformation to DLBCL 2. CD20-positive 3. Ann Arbor CS III or IV 4. Lymphoma cell count in PB?10,000/mm3 5. 20<=age<=69 6. ECOG PS 0-2 7. Bidimensionally measurable disease >1.5cm in a single dimension by CT scans 8. No prior chemotherapy, radiotherapy, interferon-alfa, or antibody therapy 9. Normal BM, hepatic, renal, cardiac, and pulmonary function 10. Written informed consent Exclusion Criteria: 1. CNS involvement 2. Glaucoma 3. DM treated by insulin 4. Uncontrollable HT 5. AP, AMI 6. Positive HBs antigen 7. seropositive to HCV 8. seropositive to HIV 9. Interstitial pneumonitis, pulmonary fibrosis, or emphysema 10. Severe infection 11. Liver cirrhosis 12. Double cancer 13. Pregnant or lactating 14. Patients who desire auto PBST after CR 15. Patients treated with major tranquilizer or antidepressant |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Japan | Aichi Medical University | Aichi-gun,Nagakute,Yazako,Karimata,21 | Aichi |
Japan | Akita University School of Medicine | Akita,Hondo,1-1-1 | Akita |
Japan | Tokyo Metropolitan Komagome Hospital | Bunkyo-ku,Honkomagome,3-18-22 | Tokyo |
Japan | Chiba Cancer Center Hospital | Chiba,Chuo-ku,Nitona-cho,666-2 | Chiba |
Japan | National Cancer Center Hospital | Chuo-kum,Tsukiji, 5-1-1 | Tokyo |
Japan | School of Medicine,Fukuoka University | Fukuoka,Jonan-ku,Nanakuma,7-45-1 | Fukuoka |
Japan | National Kyushu Cancer Center | Fukuoka,Minami-ku,Notame,3-1-1 | Fukuoka |
Japan | National Hospital Organization Kyusyu Medical Center | FukuokaChuo-ku,Jigyohama,1-8-1 | Fukuoka |
Japan | Hamamatsu University School of Medicine | Hamamatsu,Handayama,1-20-1 | Shizuoka |
Japan | Tokai University School of Medicine | Isehara,Shimokasuya,143 | Kanagawa |
Japan | Imamura Bun-in Hospital | Kagoshima,Kamoikeshinmachi,11-23 | Kagoshima |
Japan | Kagoshima University,Faculty of Medicine | Kagoshima,Sakuragaoka,8-35-1 | Kagoshima |
Japan | Kanazawa Medical University | Kahoku-gun,Uchinada-machi,Daigaku,1-1 | Ishikawa |
Japan | National Cancer Center Hospital East | Kashiwa,Kashiwanoha,6-5-1 | Chiba |
Japan | Saitama Cancer Center | Kita-adachi,Ina,Komuro,818 | Saitama |
Japan | University of Occupational and Environmental Health | Kitakyushu,Yahatanishi-ku,Iseigaoka,1-1 | Fukuoka |
Japan | Ohta Nishinouchi Hospital | Kohriyama,Nishinouchi,2-5-20 | Fukushima |
Japan | Jikei University,Daisan Hospital | Komae,Izumihoncho,4-11-1 | Tokyo |
Japan | Kumamoto University Medical School | Kumamoto,Honjo,1-1-1 | Kumamoto |
Japan | NHO Kumamoto Medical Center | Kumamoto,Ninomaru,1-5 | Kumamoto |
Japan | Kyoto Prefectural University of Medicine | Kyoto,Kamigyo-ku,Kawaramachi-Hirokoji,465 | Kyoto |
Japan | Gunma University | Maebashi,Showa,3-39-15 | Gunma |
Japan | Jikei University Hospital | Minato-ku,Nishishinbashi,3-25-8 | Tokyo |
Japan | Kyorin University School of Medicine | Mitaka,Shinkawa,6-20-2 | Tokyo |
Japan | Shiga Medical Center for Adults | Moriyama,Moriyama,5-4-30 | Shiga |
Japan | Nagasaki University Hospital | Nagasaki,Sakamoto,1-7-1 | Nagasaki |
Japan | Aichi Cancer Center Hospital | Nagoya,Chikusa-ku,Kanokoden,1-1 | Aichi |
Japan | Nagoya City University Hospital | Nagoya,Mizuho-ku,Mizuho-cho,Kawasumi,1 | Aichi |
Japan | Nagoya Medical Center | Nagoya,Naka-ku,Sannomaru,4-1-1 | Aich |
Japan | Nagoya University School of Medicine | Nagoya,Showa-ku, Tsurumai-cho,65 | Aichi |
Japan | Nagoya Daini Red Cross Hospital | Nagoya,Showa-ku,Myoken-cho,2-9 | Aichi |
Japan | Faculty of Medicine,University of Ryukyus | Nakagami,Nishihara,Uehara,207 | Okinawa |
Japan | Niigata Cancer Center Hospital | Niigata,Kawagishi-cho,2-15-3 | Niigata |
Japan | Oita Prefectural Hospital | Oita,Bunyo,476 | Oita |
Japan | Nagasaki Medical Center | Oomura,Kubara,2-1001-1 | Nagasaki |
Japan | Faculty of Medicine, Saga University | Saga,Nabeshima,5-1-1 | Saga |
Japan | Sapporo Hokuyu Hospital | Sapporo,Shiroishi-ku,Higashi-sapporo,6-5-1 | Hokkaido |
Japan | National Hospital Organization Hokkaido Cancer Center | Sapporo,Shiroishi-ku,Kikusui,4-2-3-54 | Hokkaido |
Japan | Sasebo City General Hospital | Sasebo,Hirasemachi,9-3 | Nagasaki |
Japan | Tohoku University Hospital | Sendai,Aoba-ku,Seiryo-machi,1-1 | Miyagi |
Japan | Tokyo Medical University | Shinjuku-ku,Nishi-shinjuku,6-7-1 | Tokyo |
Japan | Ehime University Hospital | Shitsukawa,Toon | Ehime |
Japan | Mie University School of Medicine | Tsu,Edobashi,2-174 | Mie |
Japan | St.Marianna University School of Medicine,Yokohama City Seibu Hospital | Yokohama,Asahi-ku,Yasashi-cho,1197-1 | Kanagawa |
Japan | University of Fukui Hospital | Yoshida-gun,Matsuoka,Shimoaizuki,23-3 | Fukui |
Lead Sponsor | Collaborator |
---|---|
Haruhiko Fukuda | Ministry of Health, Labour and Welfare, Japan |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | CR rate (phase II) | during the study conduct | No | |
Primary | PFS (phase III) | during the study conduct | No | |
Secondary | ORR, PFS, OS, Safety (phase II) | during the study conduct | Yes | |
Secondary | OS, Safety (phase III) | during the study conduct | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT03415399 -
Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma
|
Phase 1 | |
Withdrawn |
NCT03605589 -
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
|
Phase 1 | |
Recruiting |
NCT04807881 -
Phase Ib Clinical Study of Keynatinib
|
Phase 1 | |
Completed |
NCT05510596 -
Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome
|
N/A | |
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Terminated |
NCT02670317 -
Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.
|
Phase 2 | |
Completed |
NCT00998946 -
Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
|
Phase 2 | |
Terminated |
NCT00768339 -
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
|
Phase 1/Phase 2 | |
Terminated |
NCT00521638 -
Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma
|
Phase 1 | |
Withdrawn |
NCT00538096 -
A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma
|
Phase 1 | |
Completed |
NCT00379574 -
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
|
Phase 1/Phase 2 | |
Completed |
NCT00156013 -
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04594798 -
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
|
Phase 2 | |
Recruiting |
NCT04161248 -
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
|
Early Phase 1 | |
Withdrawn |
NCT04052061 -
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT04884035 -
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
|
Phase 1 | |
Not yet recruiting |
NCT05834426 -
Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers
|
||
Recruiting |
NCT05376709 -
A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population
|
N/A | |
Recruiting |
NCT04649983 -
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
|
Phase 1/Phase 2 |